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Rats exposed to a small inescapable environment are more 
active when the environment is novel than when it is familiar 
(Refs. [23,33]; see later). Recently, the empirical and theoreti-
cal interest in the behavioral activating effect of novelty has in-
creased. This interest is driven, in part, by evidence indicating 
that reactivity to a novel environment is a behavioral measure 
of a rat’s sensitivity to stress. Rats exposed to a novel environ-
ment show an increase in plasma levels of the “stress hormone” 
corticosterone (e.g., Ref. [25]). Importantly, novelty-induced 
increases in corticosterone are greater in rats that display more 
locomotor activity to an inescapable novel environment [29]. 
Moreover, rats more activated by exposure to a novel environ-
ment [often termed high responders (FIR)] displayed a greater 
increase in corticosterone levels to restraint stress than rats that 
were less reactive to the novel environment [low responders 
(LR)]. HR also had a more prolonged increase in corticosterone 
to this restraint than LR [10]. This work is important because it 
demonstrates that a purported behavioral measure of stress sen-
sitivity (i.e., novelty-induced activity) predicts the response to 
another form of stress (i.e., restraint). 
Reactivity to a novel environment has served as a pre-
dictive variable in recent drug abuse studies (see Refs. [9,31 
] for reviews). This predictive value is another reason for 
the recent interest in novelty-induced activity. For instance, 
rats that are more activated by exposure to a novel environ-
ment (HR) more readily self-administer amphetamine and 
are more sensitive to the locomotor-stimulant effects of am-
phetamine [29]. Novelty-induced activity has been found to 
also predict such behavioral effects as activity induced by 
cocaine and caffeine [16], ethanol-induced activity and eth-
anol self-administration [14,15], amphetamine-conditioned 
hyperactivity to contextual stimuli [17], cueing effects of 
amphetamine [13] and amphetamine barpress suppressant 
effects [6]. 
Another factor contributing to the interest in novelty-in-
duced activity is the potential insight it may provide into the 
behavioral and neural substrates underlying individual differ-
ences in drug abuse vulnerability. This idea is based, in part, 
on the assumption that the predictive relation just described 
likely refl ects an overlap in the mechanism(s) responsible 
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for an individual’s sensitivity to novelty and abused drugs 
[9,29,31]. Indeed, there is strong empirical evidence to sup-
port this assumption. For instance, acute and chronic loco-
motor effects of amphetamine in rats are enhanced when 
drug administration occurs in a novel rather than a familiar 
environment [3,4]. Similar enhancement of drug responses 
occurs when rats are exposed to stressors other than a novel 
environment (e.g., Refs. [1,24,30]). 
Much of the individual-differences research in rats has 
used amphetamine as the prototypical psychomotor stimulant. 
Individual differences and the psychomotor effects of nic-
otine have received much less empirical attention (see Refs. 
[28,35]). Thus, one major goal of the present report was to 
elucidate the relation between novelty-induced activity and 
the subsequent acute and chronic locomotor effects of ( –)-
nicotine-di-D tartrate. Acute nicotine can produce a biphasic 
effect on locomotor activity. Depending on such factors as 
dose and apparatus, nicotine initially suppresses locomotor 
activity in rats [7,36,37]. Chronically, nicotine tends to stim-
ulate activity [7,19,20]. There have been past reports of a pre-
dictable relation between a rat’s nondrugged activity level in 
a novel environment and its later sensitivity to the locomotor 
effects of nicotine. Rats classifi ed as HR appeared more sen-
sitive to the locomotor-depressant effects of nicotine; LR ap-
peared more sensitive to the stimulant effects of nicotine (e.g., 
Ref. [34]). Although this outcome is empirically interesting, it 
is susceptible to a baseline-dependency interpretation [11,28]. 
That is, HR may have shown greater sensitivity to the locomo-
tor-suppressant effects of nicotine simply because their base-
line activity was higher in the novel environment. Similarly, 
LR likely showed a larger relative increase in activity because 
their activity was initially lower. 
In the present report, we sought to examine whether re-
activity to novelty was related to the later sensitivity of acute 
and chronic nicotine using an experimental protocol more 
comparable to recent individual differences research with oth-
er drugs of abuse (cf. Refs. [6,16,29]; see Section 1.4). To do 
so, we had rats that were repeatedly treated with ( –)-nicotine-
di-D tartrate and an injection-matched saline control. Further, 
we assessed individual differences in a manner that was much 
less susceptible to a baseline-dependency interpretation (i.e., 
z-score transformation; see later). A second major goal of the 
present study was to determine whether the central and periph-
eral nicotinic acetylcholine (nACh) receptor antagonist meca-
mylamine or the peripheral nACh receptor antagonist hexa-
methonium affected individual differences in nicotine-treated 
rats. That is, does novelty-induced activity predict sensitivity 
to antagonism of the acute and/or chronic effects of nicotine? 
No one has assessed individual differences in the sensitivity 
to nACh receptor antagonism of the effect of nicotine. Indeed, 
there are relatively little individual differences research on the 
sensitivity to receptor antagonism whether the animal has or 
has not been treated with a drug of abuse [8]. This technique 
is an overlooked tool for identifying the processes mediating 
individual differences. 
1. Methods
1.1. Animals
The animals were 134 male Sprague-Dawley rats (mean 
body weight = 355 g) obtained from Harlan Industries (Indi-
anapolis, IN). They were housed individually in a colony that 
was on a 12-h light/dark cycle. Experiments were conducted 
during the light phase of this cycle. The rats had free access 
to food and water while in the home cage. Each rat was han-
dled for 1 min on at least 2 days prior to the start of an exper-
iment. We minimized handling experience given the evidence 
indicating that too much exposure to the experimental proto-
col could alter individual differences; this alteration is likely 
due to shifts in sensitivity to mild stressors like exposure to a 
novel environment (cf. Ref. [9]). 
1.2. Drugs 
( –)-Nicotine-di-D tartrate, mecamylamine hydrochlo-
ride (Research Biochemicals International, Natick, MA), and 
hexamethonium bromide (Sigma, St. Louis, MO) were mixed 
in saline (0.9% NaCl). The pH of nicotine was brought to 7.0 
± 0.1 with a dilute sodium hydroxide solution. Dosages were 
based on the salt form of the drug and injections were subcu-
taneous at a volume of 1 ml/kg. 
1.3. Apparatus
Activity was automatically recorded in one of eight circu-
lar chambers made from white PVC pipe. The inside diameter 
of each chamber was 30.5 cm and the top edge of the cham-
ber was 45 cm from the wire mesh fl oor. Each chamber was 
equipped with two infrared emitter/detector units. The infra-
red units were mounted 4 cm above the mesh fl oor such that 
the chamber was divided into four equal sections. Each time the 
rat broke the infrared beam, a count was automatically sent to 
an interface and then recorded by a personal computer. Activi-
ty was defi ned as the number of infrared beam breaks in prede-
termined time intervals. The chambers were located in a room 
adjacent to the animal colony. Fluorescent ceiling lights provid-
ed general illumination and a continuous white noise served to 
mask external sounds. 
1.4. Procedure
1.4.1. Mecamylamine
    Rats were assigned to one of four conditions (16 rats per condi-
tion) before baseline activity in the novel chambers was assessed. 
Novelty-induced activity for 36 rats was obtained on Day I. Each 
rat was injected subcutaneously with saline and then placed in a 
circular chamber where activity was monitored for 1 h. The re-
maining 28 rats were screened for baseline activity on Day 2. All 
rats stayed in their home cages on Day 3. Starting on Day 4, each 
rat received two injections before placement in the chamber. Two 
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sets of rats received a subcutaneous injection of mecamylamine 
(0.1 or 1.0 fi g/kg) 15 min before an injection of 1 mg/kg ( –)-nic-
otine-di-D tartrate (0.351 mg/kg free base). Immediately after the 
nicotine injection, rats were placed in the locomotor chambers 
where activity was monitored for 30 min. A third set was treat-
ed similarly except the mecamylamine injection was replaced by 
a saline injection. The last set of rats received saline for both in-
jections. This latter set provided a no-drug baseline for compari-
son. The procedures of Day 4 were repeated once daily for seven 
trials. On Day 11, all rats received a subcutaneous injection of ( –
)-nicotine-di-D tartrate (1 mg/kg) immediately before placement 
in the chamber; the pretreatment injection was precluded on this 
nicotine-alone test day. 
1.4.2. Hexamethonium
Mecamylamine blocks central and peripheral nACh recep-
tors [21]. To determine the contribution of peripheral vs. cen-
tral nACh receptors to any individual differences effect, we 
conducted an additional experiment in which rats were pre-
treated with the peripheral nACh antagonist hexamethoni-
um [2]. The four conditions (18 rats per condition except the 
saline-treated control had 16 rats) and the procedural details 
were similar to the mecamylamine experiment except that 
hexamethonium (5 or 10 fi g/kg) replaced mecamylamine and 
was injected subcutaneously 20 min before the ( –)-nicotine-
di-D tartrate injection (cf. Ref. [7]). Also, the day interven-
ing between the screen for novelty baseline and the fi rst day 
of nicotine treatment (i.e., Day 3) was eliminated. Rats had 
served in an unrelated experiment; they were drug naive and 
had never experienced the circular locomotor chambers. 
1.5. Data analysis
1.5.1. Overall activity
To allow comparison with the published literature in this 
area, we report overall activity counts (i.e., beam breaks) for 
each experiment. Initial omnibus analyses were analysis of 
variance (ANOVA); two-way repeated measure for Trials 
1–7 data and a one-way ANOVA for the nicotine-alone test. 
Post hoc tests, prompted by a signifi cant effect, were used 
to determine the source of the differences. Statistical signifi -
cance was set at a two-tailed alpha of .05. If a post hoc con-
trast was not described, then the comparison was not statisti-
cally signifi cant. 
1.5.2. Individual differences
The main goal of the present report was to determine 
whether novelty-induced activity predicted subsequent ef-
fects of nicotine and whether the antagonist mecamylamine 
or hexamethonium altered these effects in a systematic man-
ner. For each condition, we converted the total number of 
beam breaks during the 1-h exposure to the novel chamber 
to a z-score. We then divided rats in each condition into two 
groups. Rats with positive z-scores (upper portion of the ac-
tivity distribution) were designated as HR; rats with negative 
z-scores were designated LR. We then examined whether HR 
and LR differed on Trial 1, Trial 7, or the nicotine-alone test. 
Importantly, activity on these days was also converted to z-
scores before comparing HR and LR statistically with pair-
wise t tests. By normalizing the activity data with a z-score 
conversion before analyses, we could determine whether HR 
and LR on novelty-induced activity changed their relative po-
sition in the distribution across experimental treatment. That 
is, regardless of whether locomotor activity was suppressed 
or infl ated relative to inescapable novelty, all the distribu-
tions had a mean of 0 and a standard deviation of 1. Thus, 
would rats in the positive portion of the z-distribution during 
the inescapable novelty screen (i.e., HR) remain in the upper 
portion across repeated nicotine treatment? If so, this result 
would indicate that reactivity to novelty predicts nicotine-in-
duced activity. 
2. Results
2.1. Overall activity
2.1.1. Mecamylamine
   Activity in the inescapable novel environment did not dif-
fer across the four drug conditions, F < 1 (data not shown). 
Fig. 1A shows the activity counts (number of infrared beam 
breaks) across the fi rst seven trials. On Trial 5, there was a 
misalignment of an emitter/detector unit. Rather than us-
ing estimation procedures to fi ll in the missing counts for 
these rats, we dropped this trial from the analyses and fi g-
ure. There was a signifi cant effect of drug condition (F(3, 
60) = 3.23, P < .05], of trial (F(5, 300) = 22.05, P < .001] 
and a signifi cant Condition × Trial interaction (F(15, 300) 
= 15.27, P < .001 ]. Post hoc LSD tests revealed that rel-
ative to the no-drug control (0Mec/0Nic), rats treated with 
only nicotine (0Mec/1Nic) showed a signifi cant decrease in 
activity on the fi rst trial. Mecamylamine completely blocked 
this acute suppressive effect of nicotine. In fact, rats treated 
with the high dose of mecamylamine (1Mec/1Nic) increased 
activity above the no-drug control on Trial 1Mec/1Nic was 
statistically similar to the control. In contrast, the nicotine-
alone group (0Mec/1Nic) and the group pretreated with the 
low dose of mecamylamine (0.1Mec/1Nic) displayed an in-
crease in activity across trials. Group 0Mec/1Nic was sig-
nifi cantly more active than the control group on Trials 3–7. 
Group 0.1Mec/1Nic was more active than controls on Trials 
2–7; this group also differed signifi cantly from Group 0Mec/
1Nic on Trial 2. Finally, Groups 0Mec/1Nic and 0.1Mec/
1Nic were signifi cantly more active than Group 1Mec/1Nic 
on the last two trials. In short, pretreatment with mecamyl-
amine blocked nicotine-induced locomotor suppression (0.1 
and 1 mg/kg mecamylamine); the high dose of mecamyla-
mine (1 mg/kg) also blocked the subsequent locomotor-acti-
vating effects of nicotine. 
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Fig. 1B shows the overall activity counts in the nicotine-alone 
test for each group (i.e., Day 11 ). Recall that all rats received 
an injection of ( –)-nicotine-di-D tartrate (1 mg/kg) immedi-
ately before placement in the locomotor chambers; mecamyl-
amine injections were withheld on this day. The ANOVA re-
vealed a signifi cant effect of drug condition [F(3,60) = 40.31, P 
< .001]. Post hoc tests comparing each group with the no-drug 
control (0Mec/0Nic) found that Group 0Mec/1Nic was signifi -
cantly more active. This result is not surprising considering that 
this test refl ects the fi rst nicotine injection for the control group 
(i.e., acute locomotor suppression by nicotine). Rats previous-
ly treated with the low dose of mecamylamine (0.1Mec/1Nic) 
were also more active than the no-drug control group. Howev-
er, rats 7 previously treated with the high dose of mecamyla-
mine (1Mec/1Nic) did not differ from controls (0Mec/0Nic). 
Thus, in a nicotine-alone test, previous pretreatment with the 
high dose of the nACh receptor antagonist mecamylamine com-
pletely blocked tolerance to the suppressant effects of nicotine. 
That is, even though rats in Group 1Mec/1Nic had seven previ-
ous injections of nicotine, their locomotor behavior was compa-
rable to rats that had never received nicotine before this test. 
2.1.2. Hexamethonium
Novelty-induced activity did not differ statistically across 
the four conditions, F < 1 (data not shown). Fig. 2A shows 
the activity counts for each condition across the fi rst sev-
en trials. There was a signifi cant effect of trial [F(6, 396) = 
50.20, P < .001], and a signifi cant Condition × Trial interac-
tion [F(18, 396) = 18.41, P < .001]. The main effect of dose 
was not signifi cant [F(3,66) = 1.00, P = .399]. LSD tests re-
vealed that activity was suppressed by nicotine on the fi rst 
trial regardless of the hexamethonium dose. However, the 
high dose of hexamethonium (10Hex/1Nic) partially blocked 
this suppressant effect. Group 10Hex/1Nic was more active 
than the other two groups treated with nicotine. On Trial 2, 
signifi cant suppression relative to the no-drug control was 
seen in rats receiving nicotine alone (0Hex/1Nic) or the low 
dose of hexamethonium (5Hex/1Nic) but not in the rats pre-
treated with 10 mg/kg hexamethonium. Group 10Hex/1Nic 
was more active than the nicotine-alone group on Trial 2. Fi-
nally, all groups were signifi cantly more active than the no-
drug control on Trials 4–7. 
Fig. 1. Panel A shows the mean level of activity (± 1 S.E.M.) across the sev-
en trials for each drug condition in the mecamylamine experiment. The num-
ber before the letter in group names denotes the dose of drug in milligrams 
per kilogram [Mec = mecamylamine and Nic = ( –)-nicotine-di-D tartrate]. 
Panel B shows the mean activity level during the nicotine-alone test for each 
drug condition in the mecamylamine experiment. Asterisks denote a signifi -
cant difference (P < .05) from the no-drug control (0Mec/0Nic). 
Fig. 2. Panel A shows the mean level of activity (± 1 S.E.M.) across the sev-
en trials for each drug condition in the hexamethonium experiment. The num-
ber before the letter in group names denotes the dose of drug in milligrams 
per kilogram [Hex = hexamethonium and Nic = ( –)-nicotine-di-D tartrate]. 
Panel B shows the mean activity level during the nicotine-alone test for each 
drug condition in the hexamethonium experiment. Asterisks denote a signifi -
cant difference (P < .O5) from the no-drug control (0Hex/0Nic). 
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Fig. 2B shows the activity counts for each group in the nic-
otine-alone test. That is, hexamethonium was withheld and all 
rats received a 1-mg/kg injection of ( –)-nicotine-di-D tartrate 
immediately before locomotor testing. Cotreatment of hexa-
methonium and nicotine did not appear to alter the subsequent 
psychomotor effects of nicotine alone. The ANOVA revealed 
a signifi cant effect of group [F(3, 66) = 26.09, P < .001]. Con-
trasts revealed that all groups previously treated with nicotine 
were more active than the no-drug control (0Hex/0Nic) which 
was treated with nicotine for the fi rst time on this day. 
2.1.3. Individual differences
The mecamylamine and the hexamethonium experiments 
included a set of rats that received only saline for the 7 days 
following exposure to an inescapable novel environment 
(Groups 0Mec/0Nic and 0Hex/0Nic). To increase the pow-
er of our individual differences analyses, we pooled the two 
sets into one large group (n = 32) before converting the activ-
ity data for inescapable novelty, Trial 1, Trial 7, and the nic-
otine-alone test to z-scores and splitting the rats into HR and 
LR based on performance during inescapable novelty (see 
Fig. 3A). On Trials 1 and 7, HR had signifi cantly higher z-
scores than LR [t(30) ≥ 2.17, P ≤ .038]. This data pattern in-
dicates that saline control rats retained their relative position 
in the distribution even though overall activity was decreas-
ing across trials (i.e., environmental familiarization). Interest-
ingly, initial exposure to nicotine on the test day disrupted this 
difference, t < 1. Analysis of the pooled data for rats that re-
ceived only nicotine (Groups 0Mec/1Nic and 0Hex/1Nic; n = 
34) confi rmed this effect of nicotine administration (see Fig. 
38). HR did not differ statistically from LR on any day [t(32) 
≤ 1.52, P ≥ .139, indicating that nicotine, whether a locomotor 
suppressant (Trial 1) or a stimulant (Trial 7 and test), disrupt-
ed individual differences. 
Fig. 3C shows the individual differences data for rats pre-
treated with the 1-mg/kg dose of mecamylamine before each 
of the seven trials of nicotine administration (Group 1Mec/
1Nic). Mecamylamine restored the individual differences that 
were disrupted by nicotine alone (Groups 0Mec/1Nic and 
0Hex/1Nic). HR were signifi cantly greater than LR on Trials 
1 and 7 [t(14) ≥ 2.88, P ≤ .012], indicating rats classifi ed in 
the upper portion of the activity distribution during inescap-
able novelty remained there when mecamylamine was admin-
istered before nicotine. Again, nicotine alone on the test day 
disrupted the difference between HR and LR [t(14) = 1.25, P 
= .233]. Unlike mecamylamine, hexamethonium (10 mg/kg) 
did not reinstate individual differences disrupted by nicotine 
(see Fig. 3D). HR and LR were statistically similar on Trial 1, 
Trial 7, and on the nicotine-alone test day [t(16) ≤ 1.85, P ≥ 
.083]. The data from the intermediate doses of mecamylamine 
(0.1 mg/kg) and hexamethonium (5 mg/kg) are not shown be-
cause they are similar to the nicotine-alone condition and thus, 
do not add to the conclusions. 
3. Discussion
Previous research has shown that acute treatment with 
nicotine can suppress locomotor activity in rats [7,36,37]. 
Fig. 3. Panel A shows the mean z-score (± 1 S.E.M.) on Trial 1, Trial 7, and the nicotine-alone test for saline control rats classifi ed as HR and LR based on activi-
ty induced by a novel environment. Rats in the saline controls from the mecamylamine (0Mec/0Nic) and the hexamethonium (0Hex/0Nic) experiments were pooled 
into one large group. Panel B displays the mean z-score on Trial 1, Trial 7, and the nicotine-alone test for HR and LR in the groups treated with only nicotine (Groups 
0Mec/1Nic and 0Hex/1Nic). Panel C shows the mean z-scores for HR and LR pretreated with the 1-mg/kg dose of mecamylamine before each of the seven trials of 
nicotine administration (Group 1Mec/1Nic). Panel D shows the mean z-scores for HR and LR pretreated with the 10-mg/kg dose of hexamethonium before each of 
the seven trials of nicotine administration (Group 10Hex/1Nic). Asterisks denote a signifi cant difference (P < .05) from the comparable LR group. 
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Depending on the conditions of the experiment, this suppres-
sion can be quickly replaced by locomotor-activating effects 
[7,19,20]. We replicated this activity pattern in the pres-
ent set of experiments. Between-subject measures of activ-
ity (number of infrared beam breaks) revealed that 1 mg/kg 
( –)-nicotine-di-D tartrate (0.351 mg/kg free base) initially 
suppressed locomotor activity relative to saline-treated rats. 
By the fourth nicotine administration, activity counts were 
above control levels. 
One goal of the present study was to determine whether the 
initial locomotor-activating effects of novelty would be related 
to rats’ subsequent sensitivity to the psychomotor effects of nic-
otine. Previous research has found that novelty-induced activity 
can serve as a predictive variable for a rat’s sensitivity to the be-
havioral effects of abused drugs. This list of behaviors includes 
self-administration [14,15,29], drug discrimination [13], con-
text conditioning [17], bar-press suppression [6], and locomotor 
activity [16,29]. Much of the research just cited reports a pos-
itive relation between reactivity to novelty and the subsequent 
behavioral effect of interest. In contrast, we found that nicotine 
disrupted individual differences that were present in saline con-
trols. That is, HR to the fi rst exposure to an environment (i.e., 
inescapable novelty) remained more active, in general, than LR 
even after repeated exposure to the environment. Nicotine ad-
ministration (acute and chronic) disrupted this difference. Nic-
otine-induced activity for some LR was now in the upper half 
of the sampling distribution, whereas activity of some HR shift-
ed to the lower half of the distribution. Nicotine-induced dis-
ruption of individual differences occurred regardless of wheth-
er nicotine was evoking locomotor suppression (e.g., Trial 1) or 
locomotor stimulation (e.g., Trial 7). 
Our conclusion appears to be in direct contrast to that of 
previous individual differences research with nicotine (e.g., 
Ref. [34]). In that research, rats more activated by a novel en-
vironment (HR) were more sensitive to the locomotor-suppres-
sant effects of nicotine, whereas LR were more sensitive to the 
stimulant effects of nicotine. It is important to note that these 
conclusions were based on measures and statistical comparisons 
that were susceptible to a baseline-dependency interpretation 
[11,28] .That is, HR may have shown greater sensitivity to the 
locomotor-suppressant effects of nicotine simply because activ-
ity in this subset of rats was initially higher. Similarly, LR likely 
displayed a larger relative increase in activity because their ac-
tivity was initially lower. Indeed, if we assess individual differ-
ences using a within-subject shift in activity measure (i.e., nic-
otine-induced activity minus novelty-induced activity for the 
comparable time period), we observe an effect similar to past re-
search [34,35]. For example, on Trial 1 (acute nicotine), HR that 
received only nicotine treatment displayed a signifi cantly larg-
er decrease in activity (–227 ± 17) than LR (–133 ± 17). Our 
chronic nicotine data ( e.g., Trial 7) is also consistent with past 
research. According to a shift measure, LR treated chronically 
with nicotine were signifi cantly more sensitive to the activating 
effects of chronic nicotine (62 ± 16) than HR (–23 ± 17). Impor-
tantly, although the shift measures differed statistically, overall 
activity for HR and LR (number of infrared beam breaks) after 
acute and chronic administration of nicotine did not differ signif-
icantly (Trial 1: HR = 179 ± 18, LR = 152 ± 10; Trial 7: HR = 
382 ± 21, LR = 347 ± 12). This latter result is consistent with the 
z-score analyses; nicotine disrupts predictable individual differ-
ences in activity that are present in a drug-free state. 
We found that mecamylamine (1 mg/kg) completely pre-
vented the acute suppressant and chronic activating effects of 
nicotine [7,26,37]. The peripheral nACh receptor antagonist 
hexamethonium, in contrast, did not block the chronic psy-
chomotor effects of nicotine [5,7]. Interestingly, the low and 
high dose of mecamylamine (0.1 and 1 mg/kg) blocked nic-
otine-induced locomotor suppression. Unlike the high dose, 
however, the low dose of mecamylamine did not prevent the 
chronic stimulant effects of nicotine. Whether this difference 
in blockade refl ects differential sensitivity to mecamylamine 
blockade or differences in selectivity of the low and high 
dose of mecamylamine requires further empirical attention. 
Further, we found that the 10-mg/kg dose of hexamethonium 
partially blocked the acute locomotor-suppressant effect of 
nicotine. This result may indicate that nicotine-induced loco-
motor suppression is partially mediated by peripheral nACh 
receptors or that some hexamethonium at this relatively high 
dose was able to cross the blood/brain barrier and block cen-
tral nACh receptors. 
A second major goal of the present series of experiments 
was to determine if individual difference effects induced by 
nicotine were altered by mecamylamine or hexamethonium. 
Pretreatment with hexamethonium did not alter nicotine dis-
ruption of individual differences. In contrast, mecamylamine 
(1 mg/kg) restored individual differences. That is, rats which 
were classifi ed as HR based on activity in a novel environ-
ment remained HR when treated with mecamylamine 15 min 
before administration of ( –)-nicotine-di-D tartrate. Similar-
ly, LR remained in the lower portion of the distribution giv-
en mecamylamine pretreatment. For several reasons, these 
results are especially interesting. First, this data pattern in-
dicates that nicotine disrupts individual differences in activ-
ity via a centrally mediated process (i.e., neural nACh re-
ceptors). Second, and perhaps more interesting, is that these 
results suggest that mecamylamine does not merely make 
the average activity level of the group similar to saline con-
trols. Rather, mecamylamine restores the animal’s activity 
level back to its place in the group’s distribution—as if nico-
tine had not been administered. 
Corroborating this latter suggestion are the results of the 
nicotine-alone test. Recall that some rats were treated with 
nicotine and mecamylamine daily for seven trials. Trial 8 
was a test in which mecamylamine was withheld but all rats 
were treated with 1 mg/kg ( –)-nicotine-di-D tartrate just be-
fore locomotor testing. In this nicotine-alone test, rats pre-
viously treated with the high dose of mecamylamine (1 mg/
kg) were as sensitive to the locomotor-suppressant effects 
of nicotine as saline controls receiving nicotine for the fi rst 
time. Thus, chronic treatment of mecamylamine preceding 
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nicotine did not alter sensitivity to nicotine-induced loco-
motor suppression. This conclusion is further supported by 
the clear nicotine disruption of individual differences once 
mecamylamine pretreatment was withheld (Fig. 3C). Finally, 
previous experience with hexamethonium did not affect per-
formance in the nicotine-alone test, thus indicating the im-
portance of central nACh receptors. 
In sum, rats that were more active during initial exposure 
to an environment remained more active even after seven ad-
ditional 30-min exposures to the same environment. Nicotine 
treatment disrupted this effect. This nicotine disruption of in-
dividual differences occurred whether nicotine suppressed or 
stimulated locomotor activity. Mecamylamine, but not hexame-
thonium restored the nicotine-induced disruption of individu-
al differences. This result suggests that the effects of nicotine 
on individual differences were mediated by neural nACh re-
ceptors. Further research in understanding individual differenc-
es and the effects of nicotine will be important given the cur-
rent search for pharmacotherapies for smoking cessation using 
nicotine and nACh receptor antagonists like mecamylamine ( 
e.g., Ref. [32]). Humans clearly show individual differences in 
response to nicotine (e.g., Refs. [18,22,27]). Notably, not ev-
ery person exposed to nicotine via smoking tobacco becomes a 
chronic smoker [22]. Some people will attempt to smoke once 
or twice and never try again, whereas other individuals will de-
velop an abuse pattern, smoking up to several packs of ciga-
rettes a day. By determining predictors of individual vulnerabil-
ity to drugs of abuse or to pharmacotherapies meant to prevent 
relapse, researchers and practitioners may be able to develop 
better prevention and intervention strategies [12]. 
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